TW282403B - - Google Patents

Info

Publication number
TW282403B
TW282403B TW083106287A TW83106287A TW282403B TW 282403 B TW282403 B TW 282403B TW 083106287 A TW083106287 A TW 083106287A TW 83106287 A TW83106287 A TW 83106287A TW 282403 B TW282403 B TW 282403B
Authority
TW
Taiwan
Prior art keywords
protein
physiologically active
active peptide
matrix
pharmaceutical preparation
Prior art date
Application number
TW083106287A
Other languages
English (en)
Chinese (zh)
Original Assignee
Takeda Pharm Industry Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharm Industry Co Ltd filed Critical Takeda Pharm Industry Co Ltd
Application granted granted Critical
Publication of TW282403B publication Critical patent/TW282403B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
TW083106287A 1993-08-26 1994-07-12 TW282403B (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP23582393 1993-08-26

Publications (1)

Publication Number Publication Date
TW282403B true TW282403B (cs) 1996-08-01

Family

ID=16991792

Family Applications (1)

Application Number Title Priority Date Filing Date
TW083106287A TW282403B (cs) 1993-08-26 1994-07-12

Country Status (10)

Country Link
US (2) US5628993A (cs)
EP (1) EP0640336B1 (cs)
JP (1) JPH07112940A (cs)
KR (1) KR100338400B1 (cs)
CN (1) CN1105557C (cs)
AT (1) ATE148625T1 (cs)
CA (1) CA2130868A1 (cs)
DE (1) DE69401691T2 (cs)
DK (1) DK0640336T3 (cs)
TW (1) TW282403B (cs)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07112940A (ja) * 1993-08-26 1995-05-02 Takeda Chem Ind Ltd 徐放性非経口投与製剤およびその製造方法
JP4330175B2 (ja) * 1995-06-07 2009-09-16 デュレクト コーポレイション 高粘度液体による制御された送達系
US7833543B2 (en) * 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US6413536B1 (en) * 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US6509313B1 (en) * 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
ATE516034T1 (de) * 1997-01-02 2011-07-15 Univ Jefferson Verfahren zur modulation der immunreaktion in einem infektierten säugetier mittels transmukosales eingeben eines modulationsmittel
US5948407A (en) * 1997-03-19 1999-09-07 Shire Laboratories Inc. Oral induction of tolerance to parenterally administered non-autologous polypeptides
US6051558A (en) * 1997-05-28 2000-04-18 Southern Biosystems, Inc. Compositions suitable for controlled release of the hormone GnRH and its analogs
US20060025328A1 (en) * 1997-05-28 2006-02-02 Burns Patrick J Compositions suitable for controlled release of the hormone GnRH and its analogs
RU2271196C2 (ru) * 1999-06-04 2006-03-10 Элзэ Копэрейшн Имплантируемая композиция (варианты) и способ ее приготовления
EP1949890A3 (en) 1999-06-04 2011-05-18 ALZA Corporation Implantable gel compositions and method of manufacture
JP2001058955A (ja) * 1999-06-17 2001-03-06 Inst Of Physical & Chemical Res 生理活性ペプチド徐放性製剤
US20040047910A1 (en) * 2000-07-07 2004-03-11 Christian Beckett Suppository and composition comprising at least one polyethylene glycol
US7030127B2 (en) * 2001-06-29 2006-04-18 Ethicon, Inc. Composition and medical devices utilizing bioabsorbable polymeric waxes
US6967234B2 (en) * 2002-12-18 2005-11-22 Ethicon, Inc. Alkyd-lactone copolymers for medical applications
US7034037B2 (en) * 2001-06-29 2006-04-25 Ethicon, Inc. Compositions and medical devices utilizing bioabsorbable polymeric waxes and rapamycin
CN1585627A (zh) 2001-09-14 2005-02-23 弗朗西斯J·马丁 用于持续释放治疗剂的显微制作的纳米微孔装置
AU2002366267B2 (en) 2001-11-19 2007-05-10 Becton, Dickinson And Company Pharmaceutical compositions in particulate form
US7005136B2 (en) * 2002-03-29 2006-02-28 Ethicon, Inc. Bone replacement materials utilizing bioabsorbable liquid polymers
US7326426B2 (en) 2002-03-29 2008-02-05 Ethicon, Inc. Compositions and medical devices utilizing bioabsorbable liquid polymers
US7368125B2 (en) * 2002-06-05 2008-05-06 Ethicon, Inc. Amphiphilic polymers for medical applications
US7026374B2 (en) * 2002-06-25 2006-04-11 Aruna Nathan Injectable microdispersions for medical applications
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
US7101566B2 (en) * 2002-06-28 2006-09-05 Ethicon, Inc. Polymer coated microparticles for sustained release
DK1575569T3 (da) 2002-12-13 2011-01-10 Durect Corp Oralt indgivelsessystem omfattende flydende bærematerialer med høj viskositet
US6872799B2 (en) * 2002-12-18 2005-03-29 Ethicon, Inc. Functionalized polymers for medical applications
US6866860B2 (en) * 2002-12-19 2005-03-15 Ethicon, Inc. Cationic alkyd polyesters for medical applications
US20040120981A1 (en) * 2002-12-20 2004-06-24 Aruna Nathan Crosslinked alkyd polyesters for medical applications
AU2004251541B2 (en) 2003-06-27 2010-03-04 Otsuka Pharmaceutical Co., Ltd. Sustained drug-release particles and process for producing the same
WO2005044236A1 (en) * 2003-10-27 2005-05-19 Control Delivery Systems, Inc. Suspension delivery system for the sustained and controlled local release of pharmaceuticals
KR100486028B1 (ko) * 2004-04-20 2005-05-03 주식회사 펩트론 단백질 함유 서방성 리피드 임플란트 및 이의 제조방법
AU2005325213B2 (en) * 2004-08-04 2010-10-07 Evonik Corporation Methods for manufacturing delivery devices and devices thereof
EA014852B1 (ru) 2004-09-17 2011-02-28 Дьюрект Корпорейшн Система контролируемой доставки
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
ES2643140T3 (es) * 2005-12-22 2017-11-21 Oakwood Laboratories L.L.C. Sistema de suministro de liberación lenta sublimable y procedimiento de realización del mismo
PT2117521E (pt) 2006-11-03 2012-09-10 Durect Corp Sistemas de administração transdérmica que compreendem bupivacaína
AU2008347158B8 (en) 2007-12-06 2013-08-22 Durect Corporation Oral pharmaceutical dosage forms
ES2718612T3 (es) 2007-12-20 2019-07-03 Evonik Corp Procedimiento para preparar micropartículas que tienen un bajo volumen de disolvente residual
ES2441550T3 (es) * 2007-12-21 2014-02-05 Ludwig-Maximilians-Universität Dispositivos extruidos con forma de varilla para la Iiberación controlada de sustancias biológicas a humanos y animales
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
US9532946B2 (en) 2012-11-20 2017-01-03 Intervet Inc. Manufacturing of semi-plastic pharmaceutical dosage units
CN105120659A (zh) 2013-03-15 2015-12-02 度瑞公司 用于降低溶解可变性的具有流变改性剂的组合物
CN115666621A (zh) 2020-01-13 2023-01-31 度勒科特公司 具有减少的杂质的持续释放药物递送系统及相关方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1257199A (en) * 1986-05-20 1989-07-11 Paul Y. Wang Preparation containing bioactive macromolecular substance for multi-months release in vivo
NZ231281A (en) * 1988-11-08 1991-01-29 Takeda Chemical Industries Ltd Sustained release pharmaceutical preparations comprising the active agent dispersed in a solid matrix of a fatty acid ester of a polyglycerol
CA2020654A1 (en) * 1989-07-07 1991-01-08 Yohko Akiyama Stabilized fgf composition and production thereof
JP3078859B2 (ja) * 1990-02-23 2000-08-21 武田薬品工業株式会社 安定な放出制御性製剤用コーティング剤
IE65045B1 (en) * 1990-04-28 1995-10-04 Takeda Chemical Industries Ltd Granulated preparations and method of producing the same
TW209174B (cs) * 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
IL103275A0 (en) * 1991-10-01 1993-02-21 Lilly Co Eli Injectable extended release formulations and methods
YU87892A (sh) * 1991-10-01 1995-12-04 Eli Lilly And Company Lilly Corporate Center Injektibilne formulacije produženog otpuštanja i postupci za njihovo dobijanje i primenu
JPH06219960A (ja) * 1993-01-25 1994-08-09 Takeda Chem Ind Ltd 生理活性ポリペプチド含有組成物の製造法
JPH07112940A (ja) * 1993-08-26 1995-05-02 Takeda Chem Ind Ltd 徐放性非経口投与製剤およびその製造方法

Also Published As

Publication number Publication date
EP0640336B1 (en) 1997-02-05
JPH07112940A (ja) 1995-05-02
EP0640336A1 (en) 1995-03-01
KR100338400B1 (ko) 2002-11-22
DE69401691D1 (de) 1997-03-20
CN1105557C (zh) 2003-04-16
CN1104488A (zh) 1995-07-05
ATE148625T1 (de) 1997-02-15
KR950005329A (ko) 1995-03-20
CA2130868A1 (en) 1995-02-27
DE69401691T2 (de) 1997-07-17
DK0640336T3 (da) 1997-04-01
US5628993A (en) 1997-05-13
US5750100A (en) 1998-05-12

Similar Documents

Publication Publication Date Title
TW282403B (cs)
IL85523A (en) Stable alpha interferon complex,its preparation and pharmaceutical compositions comprising it
ZA896149B (en) Pharmaceutical formulation for the treatment of diabetes mellitus
IL109403A0 (en) Oral drug delivery compositions and methods
GR880300058T1 (en) Pharmaceutical compositions containing levodopa methyl ester, preparation and therapeutic applications thereof
DE69228704D1 (de) Stabilisierte pharmazeutische formulierung, die wachstumshormon und asparagin enthält
HK1048058A1 (zh) 肝臟選擇性的藥用活性物
CA2058835A1 (en) Stable pharmaceutical composition and method for its production
EP0368339A3 (en) Pharmaceutical preparation for percutaneous administration containing bunazosin or its salt
IT1235053B (it) Metodi per la preparazione di composizioni farmaceutiche a base di bromocriptina dotate di elevata stabilita' e prodotti derivanti.
HUT52374A (en) Process for producing pharmaceutical compositions
IL79816A0 (en) Pharmaceutical composition comprising a drug-polymer matrix
CA2025070A1 (en) Recombinant aprotinin variants genetically engineered process for the microbial preparation of homgeneously processed aprotinin variants and the therapeutic use thereof
NZ236474A (en) 4,5-diphenyl-2-oxazole octanoic, nonanoic and decanoic acid and ester derivatives, preparation and pharmaceutical compositions thereof
IL105214A0 (en) 7-oxo-7h-pyrido(1,2,3-de)(1,4)benzoxazine-6-carboxylic acids and their esters,their preparation and pharmaceutical compositions containing them
WO1992012960A3 (en) Derivatives of dicarboxylic acids having six to twelve carbon atoms and use of these derivatives and dicarboxylic acids alone in the preparation of pharmaceutical compositions for enteral and parenteral nutrition
IL85144A0 (en) Controlled and delayed release oral pharmaceutical compositions and their preparation
ATE136778T1 (de) Oral anzuwendende arzneimittel dapiprazol enthaltend
FR2684878B1 (fr) Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation.
IL82639A0 (en) Transdermal pharmaceutical composition
ES8704176A1 (es) Un procedimiento para preparar hidrocloruro de bacampicili- na,protegido de la degradacion por almacenamiento en presen-cia de vapor de agua
MX9604539A (es) Aminoacidos modificados para la distribucion de farmaco.